Skip to main content
Premium Trial:

Request an Annual Quote

Citing Sluggish Protein Biomarker and Testing Business, NextGen Enters $1M Loan Agreement

Premium

Citing lower than expected sales in its biomarker and testing business, protein biomarker firm NextGen Group said this week it has entered a convertible loan agreement with Alpha 4 Concepts for the provision of additional funding of £650,000 ($1.04 million).

The funding is required "in order to continue to fund the working capital requirements of the [firm] and the investments in the diagnostic business," the company said. It added that it expects that it will require further funding in the first quarter of 2012.

The loan was made at 12 percent interest for a period ending Oct. 31, 2012, and is convertible at the lender's option into ordinary shares in NextGen at a price of 0.1p per share plus one warrant for every share issued.

During the first half of 2011, NextGen embarked upon a reorganization of its business, moving into the plasma biomarker discovery space by launching a series of protein biomarker panels aimed at various therapeutic areas (PM 3/18/2011).

Previously the company had focused on providing custom biomarker services for pharma and biotech firms. Barry McAleer, CEO of NextGen Sciences, a wholly owned subsidiary of NextGen Group, told ProteoMonitor upon the launch of the panels that moving into the discovery panel space was an immediate tactical approach to generating cash, as well as "a way of finding more lucrative projects" in the diagnostics and personalized medicine space.

In September the company reported $948,279 in revenues for the first half of 2011, up 34 percent from $708,831 in the prior-year period. It posted a net loss of $1.59 million, down from $1.74 million in H1 2010.

It also disclosed in September that it had inked a $700,000 deal in June with an undisclosed client for biomarker qualification using its plasmadiscovery41 product. In August NextGen announced it had signed an agreement with the University of Nebraska for use of its csfdiscovery43 biomarker discovery assay to investigate biomarkers associated with cognitive abnormalities in patients chronically infected with HIV (PM 8/19/2011).

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.